1. World Health Organization. Global tuberculosis report 2018. www.who.int/tb/publications/global_report/en/ (accessed 28 Juni 2018)
2. Badan Pusat Statistik, 2017. Statistik Kesejahteraan Rakyat 2017, Jakarta.
3. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta‐analysis. BMJ 2014;349:g4643. [DOI: 10.1136/bmj.g4643]
4. Altenburg AF, Kreijtz JH, Vries RD, Song F, Fux R, Rimmelzwaan GF, et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 2014;6(7):2735‐61.
5. Kashangura R, Julien S, Garner P, Johnson S. MVA85A vaccine to enhance BCG for preventing tuberculosis. CochraneDatabase of Systematic Reviews 2019, Issue 4. Art. No.: CD012915. DOI: 10.1002/14651858.CD012915.pub2.
6. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381(9871):1021–8.
7. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine 2015;3(3): 190–200.
8. Nemes E, Hesseling A, Tameris M, Mauff K, Downing K, Mulenga H, et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial. Clinical Infectious Diseases 2018;66(4):554–63. DOI: 10.1093/cid/cix834